XML 77 R67.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SEGMENT REPORTING - Revenue (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Mar. 28, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
segment
Jun. 30, 2023
USD ($)
Segment reporting          
Number of operating segments | segment       2  
Total net revenues   $ 138,040 $ 116,547 $ 275,470 $ 223,333
Depreciation and amortization   14,697 14,690 29,383 29,390
Corporate and other unallocated expenses   52,821 38,760 100,842 75,228
Operating Income   5,169 12,402 25,481 22,297
Unrealized (loss) gain on investment in equity securities   (2,712) 0 6,943 0
Interest expense, net   (4,656) (7,100) (9,256) (14,796)
Other expense, net   (88) (53) (120) (87)
(Loss) Income Before Income Tax Expense (Benefit)   (2,287) 5,249 23,048 7,414
Disposal Group, Held-for-Sale, Not Discontinued Operations | Oakville, Ontario Former Manufacturing Facility          
Segment reporting          
Gain on sale of property $ 5,300        
Operating Segments | Generics, Established Brands, and Other          
Segment reporting          
Total net revenues   88,847 92,243 189,340 182,699
EBITDA   31,631 39,937 76,937 78,765
Operating Segments | Rare Disease          
Segment reporting          
Total net revenues   49,193 24,304 86,130 40,634
EBITDA   4,344 4,215 4,740 2,964
Corporate, Non-Segment          
Segment reporting          
Depreciation and amortization   (14,697) (14,690) (29,383) (29,390)
Corporate and other unallocated expenses   (16,109) (17,060) (26,813) (30,042)
Operating Income   5,169 12,402 25,481 22,297
Unrealized (loss) gain on investment in equity securities   (2,712) 0 6,943 0
Interest expense, net   (4,656) (7,100) (9,256) (14,796)
Other expense, net   $ (88) $ (53) $ (120) $ (87)